{"title": "Vaccine success and challenges in northern Australia", "author": "Bianca F Middleton; Jane Davies; Rosalind Webby", "url": "https://www.publish.csiro.au/ma/MA22036", "hostname": "csiro.au", "description": "Aboriginal and Torres Strait Islander people living in rural and remote Australia have lower vaccine coverage rates and experience higher rates of notification and hospitalisations for vaccine preventable diseases than non-Aboriginal people. This paper explores important public health and research activities being undertaken in the Northern Territory to reduce this disparity in vaccine program performance, with a particular focus on rotavirus, meningococcal, human papilloma virus and COVID-19 vaccines.", "sitename": "CSIRO PUBLISHING", "date": "2022-08-25", "cleaned_text": "Vaccine success and challenges in northern AustraliaBianca F. Middleton A * , Jane Davies A B and Rosalind Webby C A Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, PO Box 41096, Casuarina, NT, Australia. B Department of Infectious Diseases, Royal Darwin and Palmerston Hospitals, Darwin, NT, Australia. C Northern Territory Health, Darwin, NT, Australia. | | Bianca Middleton is paediatrician at the Royal Darwin Hospital and PhD student at Menzies School of Health Research. Her research interests include rotavirus vaccines and vaccine preventable diseases of childhood. | | Jane Davies is the Co-Director of Infectious Diseases at Royal Darwin Hospital and a Principal Research Fellow at Menzies School of Health Research. Her research focuses on providing evidence to improve care for infectious diseases. | | Rosalind Webby is a Public Health Physician with NT Health and was previously Head of Immunisation at the Northern Territory Centre for Disease Control. [bianca.middleton@menzies.edu.au](mailto:bianca.middleton@menzies.edu.au) Microbiology Australia 43(3) 113-116 Author(s) (or their employer(s)). Published by CSIRO Publishing on behalf of the ASM. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License ( [CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)) Abstract Aboriginal and Torres Strait Islander people living in rural and remote Australia have lower vaccine coverage rates and experience higher rates of notification and hospitalisations for vaccine preventable diseases than non-Aboriginal people. This paper explores important public health and research activities being undertaken in the Northern Territory to reduce this disparity in vaccine program performance, with a particular focus on rotavirus, meningococcal, human papilloma virus and COVID-19 vaccines. Keywords: Aboriginal and Torres Strait Islander, COVID-19, human papilloma virus, immunisation, meningococcal, Northern Territory, rotavirus, vaccine. References[1] Hull B et al. (2021) Annual Immunisation Coverage Report 2020. National Centre for Immunisation Research and Surveillance, Sydney. [2] Henschke, N et al.. (2022) The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine 40, 1707-11. | [The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.Crossref](https://doi.org/10.1016/j.vaccine.2022.02.003)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality.&journal=Vaccine&volume=40&pages=1707-11&publication_year=2022&author=N%20Henschke&hl=en&doi=10.1016/j.vaccine.2022.02.003)| [3] Galati, JC et al.. (2006) The burden of rotavirus-related illness among young children on the Australian health care system. Aust NZ J Public Health 30, 416-21. | [The burden of rotavirus-related illness among young children on the Australian health care system.Crossref](https://doi.org/10.1111/j.1467-842X.2006.tb00456.x)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=The burden of rotavirus-related illness among young children on the Australian health care system.&journal=Aust NZ J Public Health&volume=30&pages=416-21&publication_year=2006&author=JC%20Galati&hl=en&doi=10.1111/j.1467-842X.2006.tb00456.x)| [4] Newall, AT et al.. (2006) Burden of severe rotavirus disease in Australia. J Paediatr Child Health 42, 521-7. | [Burden of severe rotavirus disease in [5] Schultz, R (2006) Rotavirus gastroenteritis the Northern 1995-2004. Med J Aust 185, 354-6. | Northern the Northern Territory, 1995-2004.&journal=Med J Aust&volume=185&pages=354-6&publication_year=2006&author=R%20Schultz&hl=en&doi=10.5694/j.1326-5377.2006.tb00609.x)| [6] Dey, A et al.. (2012) Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program. Med J Aust 197, 453-7. | [Changes in hospitalisations for acute gastroenteritis Australia the national rotavirus vaccination program.Crossref](https://doi.org/10.5694/mja12.10062)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Changes in hospitalisations for acute gastroenteritis rotavirus vaccination program.&journal=Med J Aust&volume=197&pages=453-7&publication_year=2012&author=A%20Dey&hl=en&doi=10.5694/mja12.10062)| [7] Snelling, TL et al.. (2011) Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 52, 191-9. | [Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia.Crossref](https://doi.org/10.1093/cid/ciq101)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia.&journal=Clin Infect Dis&volume=52&pages=191-9&publication_year=2011&author=TL%20Snelling&hl=en&doi=10.1093/cid/ciq101)| [8] Middleton, al.. (2020) Retrospective case-control study of 2017 G2P[4] rotavirus epidemic in rural and remote Australia. | [Retrospective case-control study of study of rural and remote Australia.&journal=Pathogens&volume=9&pages=790-&publication_year=2020&author=BF%20Middleton&hl=en&doi=10.3390/pathogens9100790)| [9] Hull, B et al.. (2013) Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience. Vaccine 31, 1964-9. | [Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience.Crossref](https://doi.org/10.1016/j.vaccine.2013.02.007)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Impact of the introduction of rotavirus vaccine on the timeliness of other scheduled vaccines: the Australian experience.&journal=Vaccine&volume=31&pages=1964-9&publication_year=2013&author=B%20Hull&hl=en&doi=10.1016/j.vaccine.2013.02.007)| [10] Ioannides, S et al.. (2019) Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2011-2015. Commun Dis Intell 43, . | [Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2011-2015.Crossref](https://doi.org/10.33321/cdi.2019.43.36)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander People, Australia, 2011-2015.&journal=Commun Dis Intell&volume=43&pages=-&publication_year=2019&author=S%20Ioannides&hl=en&doi=10.33321/cdi.2019.43.36)| [11] Middleton, BF et al.. (2019) trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis. BMJ Open 9, e032549. | phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis.Crossref](https://doi.org/10.1136/bmjopen-2019-032549)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=The ORVAC trial protocol: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis.&journal=BMJ Open&volume=9&pages=e032549-&publication_year=2019&author=BF%20Middleton&hl=en&doi=10.1136/bmjopen-2019-032549)| [12] Middleton, BF et al.. (2022) Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial. J Infect Dis , jiac038. | [Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial.Crossref](https://doi.org/10.1093/infdis/jiac038)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, clinical [13] (2013) Rotavirus vaccines WHO position paper: January 2013 - recommendations. Vaccine 31, 6170-1. | [Rotavirus vaccines WHO position paper: January 2013 - recommendations.Crossref](https://doi.org/10.1016/j.vaccine.2013.05.037)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Rotavirus vaccines WHO position paper: January 2013 - recommendations.&journal=Vaccine&volume=31&pages=6170-1&publication_year=2013&author=%20&hl=en&doi=10.1016/j.vaccine.2013.05.037)| [14] Lu, HL et al.. (2019) Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and Netw Open 2, e1912458. | [Association between and risk of intussusception among neonates and infants: a systematic review and meta-analysis.Crossref](https://doi.org/10.1001/jamanetworkopen.2019.12458)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Association between rotavirus vaccination and risk of intussusception (2017) Meningococcal serogroup W and Y disease on the rise. NT Dis Control Bull 24, 12-4. [16] Webby, R (2018) Update on meningococcal disease in the Northern Territory (NT). NT Dis Control Bull 25, 23-8. [17] Janagaraj, P and Webby, R (2018) Meningococcal W update, March 31 2018. NT Dis Control Bull 25, 29-30. [18] Webby, R (2019) Northern Territory meningococcal ACWY vaccination program rollout and coverage, June 2019. NT Centre Dis Control Bull 26, 1-2. [19] Lahra, MM et al.. (2021) Australian Meningococcal Surveillance Programme Annual Report, 2020. Commun Dis Intell 45, . | Programme Annual Report, 2020.&journal=Commun Dis Intell&volume=45&pages=-&publication_year=2021&author=MM%20Lahra&hl=en&doi=10.33321/cdi.2021.45.46)| [20] Marshall, HS et al.. (2022) An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern Territory, Australia\u2014study protocol. Vaccines 10, 309. | [An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern Territory, Australia\u2014study protocol.Crossref](https://doi.org/10.3390/vaccines10020309)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=An observational study to assess the effectiveness of 4CMenB against meningococcal disease and carriage and gonorrhea in adolescents in the Northern Territory, Australia\u2014study protocol.&journal=Vaccines&volume=10&pages=309-&publication_year=2022&author=HS%20Marshall&hl=en&doi=10.3390/vaccines10020309)| [21] Nagy, C and Graham, J (2007) Cervical cancer vaccination - Human Papillomavirus Vaccination Program launched. NT Dis Control Bull 14, 1-3. [22] NCIRS factsheet. Human papillomavirus vaccines for Australians: immunisation providers. [https://www.ncirs.org.au/sites/default/files/2018-12/HPV%20Factsheet_2018%20Aug%20Update_final%20for%20web.pdf](https://www.ncirs.org.au/sites/default/files/2018-12/HPV%20Factsheet_2018%20Aug%20Update_final%20for%20web.pdf)(accessed 4 June 2022). [23] Condon, JR et al.. (2005) Cancer incidence and survival for indigenous Australians in the Northern Territory. Aust NZ J Public Health 29, 123-8. | [Cancer incidence and survival for indigenous Australians in the Northern Territory.Crossref](https://doi.org/10.1111/j.1467-842X.2005.tb00061.x)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Cancer incidence and survival for indigenous Australians in the Northern Territory.&journal=Aust NZ J Public Health&volume=29&pages=123-8&publication_year=2005&author=JR%20Condon&hl=en&doi=10.1111/j.1467-842X.2005.tb00061.x)| [24] Murray, S (2008) Update on the HPV program and National HPV register. NT Dis Control Bull 15, 11-2. [25] Patel, C et al.. (2018) The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill 23, 1700737. | [The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?Crossref](https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?&journal=Euro Surveill&volume=23&pages=1700737-&publication_year=2018&author=C%20Patel&hl=en&doi=10.2807/1560-7917.ES.2018.23.41.1700737)| [26] NHMRC Centre of Research Excellence in Cancer Control (2021) Cervical Cancer Elimination Progress Report: Australia's progress towards the elimination of cervical cancer as a public health problem, Melbourne, Australia. [https://www.cervicalcancercontrol.org.au](https://www.cervicalcancercontrol.org.au) [27] O'Sullivan, D et al.. (2020) The impact and implications of COVID-19: an Australian perspective. Int J Commun Soc Dev 2, 134-51. | [The impact and implications of COVID-19: an Australian perspective.Crossref](https://doi.org/10.1177/2516602620937922)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=The impact and implications Commun Soc et al.. (2022) Local genomic sequencing enhances COVID-19 surveillance in the Northern Territory of Australia. Pathology 54, 659-62. | [Local genomic sequencing enhances COVID-19 surveillance Territory of Australia.Crossref](https://doi.org/10.1016/j.pathol.2022.03.005)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=Local genomic sequencing enhances COVID-19 surveillance in the Territory of Australia.&journal=Pathology&volume=54&pages=659-62&publication_year=2022&author=EM%20Meumann&hl=en&doi=10.1016/j.pathol.2022.03.005)| [29] Komesaroff, PA et al.. (2021) COVID-19 restrictions should only be lifted when it is safe to do so for Aboriginal communities. Intern Med J 51, 1806-9. | [COVID-19 restrictions should only be lifted when it is safe to do so for Aboriginal communities.Crossref](https://doi.org/10.1111/imj.15559)| [GoogleScholarGoogle Scholar](https://scholar.google.com/scholar_lookup?title=COVID-19 restrictions should only be lifted when it is safe to do so for Aboriginal communities.&journal=Intern Med J&volume=51&pages=1806-9&publication_year=2021&author=PA%20Komesaroff&hl=en&doi=10.1111/imj.15559)| [30] Kerrigan, V et al.. (2021) Stay strong: Aboriginal leaders deliver COVID-19 health messages. Health Promot J Austr 32, 203-4. | [Stay COVID-19 health messages.Crossref](https://doi.org/10.1002/hpja.364)| Scholar](https://scholar.google.com/scholar_lookup?title=Stay leaders deliver COVID-19 J Austr&volume=32&pages=203-4&publication_year=2021&author=V%20Kerrigan&hl=en&doi=10.1002/hpja.364)| [31] Northern Territory Government (2022) COVID Vaccine Operational Report. "}